Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.
Riley Kandel
Advertisement
Articles by Riley Kandel
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: Clinical Advancements and FDA News
2
Beyond Chemotherapy: Evaluating the Efficacy of Ribociclib, Letrozole in LGSOC
3
The Strategic Shift in SCLC Management: Bone Marrow Preservation
4
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
5